Abiraterone, a CYP17 inhibitor, is used in combination with prednisone in patients with metastatic Castration Resistant Prostate Cancer (mCRPC) who have received prior docetaxel chemotherapy as a third-line treatment for prostate cancer.
Specifically:
Patients with general prostate cancer are sensitive to endocrine therapy in the early stages of treatment and are treated with debulking therapy, which is highly effective.
After a period of treatment, some patients develop hormone resistance and metastasis, transforming into mCRPC.
mCRPC is still not controlled after chemotherapy with docetaxel and other chemotherapy, abiraterone and prednisone can be used The combination therapy can achieve some efficacy.